Moderna, Inc. (NASDAQ:MRNA)

PRESS RELEASE

published on 06/06/2024 at 13:00, 1 year 10 months ago

Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
Moderna's mRNA-3705 selected for FDA's START pilot program to address rare diseases. The investigational mRNA therapeutic aims to treat methylmalonic acidemia due to MUT deficiency with innovative mRNA platform

Moderna Rare Diseases MMA MRNA-3705 START Pilot Program
PRESS RELEASE

published on 06/03/2024 at 14:00, 1 year 10 months ago

Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage II
BRIEF

published on 05/31/2024 at 17:03, 1 year 11 months ago

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA

FDA Approval Moderna Vaccine RSV MRESVIA
PRESS RELEASE

published on 05/31/2024 at 16:58, 1 year 11 months ago

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
Moderna gains FDA approval for mRESVIA, a single-dose pre-filled syringe RSV vaccine for adults 60+ to prevent lower respiratory tract disease. Second mRNA product and breakthrough therapy designation

FDA Approval Moderna RSV Vaccine MRNA MRESVIA
BRIEF

published on 05/22/2024 at 13:05, 1 year 11 months ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting

Clinical Trials Immunotherapy Moderna ASCO 2024 MRNA-4157
PRESS RELEASE

published on 05/22/2024 at 13:00, 1 year 11 months ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
Moderna to host an investor event via webcast on June 3 at 6:15 PM CDT. Abstracts on mRNA-4157 for ASCO Annual Meeting. Details on mRNA-4157 (V940) therapy development

Webcast Moderna Investor Event MRNA-4157 Neoantigen Therapy
BRIEF

published on 05/13/2024 at 13:05, 1 year 11 months ago

Moderna Announces Participation in Key Investor Conferences

Investor Conferences Healthcare Financial Markets Moderna Webcasts
PRESS RELEASE

published on 05/13/2024 at 13:00, 1 year 11 months ago

Moderna to Present at Upcoming Conferences in May/June 2024
Moderna, Inc. to participate in upcoming investor conferences, showcasing its leadership in mRNA medicine and innovative approach to disease treatment. Live webcasts available

Investor Conferences Moderna Inc. MRNA Medicine Webcasts Disease Treatment
BRIEF

published on 05/02/2024 at 12:35, 2 years ago

Moderna Reports Q1 2024 Financial Performance and Strategic Progress

Financial Results MRNA Technology Moderna RSV Vaccine Vaccine Development
PRESS RELEASE

published on 05/02/2024 at 12:30, 2 years ago

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Moderna, Inc. reports Q1 revenues of $167 million, GAAP net loss of $1.2 billion, and diluted EPS of $(3.07). Company prepares for RSV vaccine and Spikevax® 2024-2025 formula launches, with expected product sales of $4 billion in 2024

Moderna Inc. Net Loss RSV Vaccine Q1 Revenues Spikevax 2024-2025 Formula

Published on 05/02/2026 at 21:00, 10 hours 38 minutes ago

GECC Subsidiary Provides Update on its Lawsuit for Damages Against the Lender of the Atmosphere Project
Published on 05/02/2026 at 01:30, 1 day 6 hours ago

Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Published on 05/02/2026 at 00:50, 1 day 6 hours ago

CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/02/2026 at 00:00, 1 day 7 hours ago

Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 1 day 7 hours ago

Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies

View all ACCESSWIRE

Published on 05/03/2026 at 04:45, 2 hours 52 minutes ago

GWM Unveils World-Class Safety & Testing Facilities: Safety Built on Data, Not Hype
Published on 05/02/2026 at 15:35, 16 hours 2 minutes ago

Ecuador's banana sector renews labor agreement, with jobs meeting global standards
Published on 05/01/2026 at 19:23, 1 day 12 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 18:40, 1 day 12 hours ago

Holding(s) in Company
Published on 05/01/2026 at 17:47, 1 day 13 hours ago

Key Figures 30.04.2026

View all EQS

Published on 04/30/2026 at 20:00, 2 days 11 hours ago

AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 2 days 12 hours ago

AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 2 days 12 hours ago

Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 2 days 13 hours ago

Minutes of the Combined General Meeting held on April 30, 2026
Published on 04/30/2026 at 18:00, 2 days 13 hours ago

TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

News